Androgen deprivation therapy (ADT) is commonly used in the treatment of prostate cancer and is associated with several side effects including psychiatric disorders.
We present an unusual case of a 62-year-old man with high risk prostate cancer that developed de novo psychosis after starting luteinizing hormone-releasing hormone (LHRH) agonists and discuss possible mechanisms to explain such findings. This case report highlights the importance of continuing assessment and monitoring of potential emotional and behavioral symptoms in prostate cancer patients treated with ADT.
Written by:
Bernad DM, Dal Pra A, Baule C, Frey BN, Faria S. Are you the author?
Montreal General Hospital, McGill University Health Centre, Montreal, Quebec, Canada.
Reference: Can J Urol. 2013 Aug;20(4):6868-70.
PubMed Abstract
PMID: 23930615
UroToday.com Prostate Cancer Section
